|
|
The Biomedical & Life Sciences Collection
Latest
Releases
|
|
|
|
The immunology
underlying rheumatic diseases
Dr.
Hussein Al-Mossawi
University of Oxford, UK
|
|
|
|
|
|
The emergence of the
SARS-CoV-2 Omicron variant
Prof.
Emma Thomson
University of Glasgow, UK
|
|
|
|
|
|
How is Omicron
different?
Prof.
Emma Thomson
University of Glasgow, UK
|
|
|
|
|
|
The mononuclear phagocyte
system - tissue resident macrophages: distribution and functions
Prof.
Emeritus Siamon Gordon
University of Oxford, UK
|
|
|
|
|
|
The mononuclear
phagocyte system: tissue resident macrophages - activation and regulation
Prof.
Emeritus Siamon Gordon
University of Oxford, UK
|
|
|
|
|
|
Signal transduction by
leukocyte receptors
Dr.
Omer Dushek
University of Oxford, UK
|
|
|
|
|
|
Lineage decisions in
the thymus: T cell lineage commitment
Prof.
Bruno Silva-Santos
University of Lisbon, Portugal
|
|
|
|
|
|
Lineage decisions in
the thymus: αβ and γδ T cell lineages
Prof.
Bruno Silva-Santos
University of Lisbon, Portugal
|
|
|
|
|
|
Modulating gene
expression to treat diseases
Dr.
Navneet Matharu
University of California San Francisco, USA
|
|
|
|
|
|
Regulation of ATMPs in
Europe: present and future
Dr.
Ana Hidalgo-Simon
European Medicines Agency, The Netherlands
|
|
|
|
|
|
Immunotherapy: CARs on
the fast-track to treat cancer
Dr.
Joseph A. Fraietta
University of Pennsylvania, USA
|
|
|
|
|
Live Webinar: Treating autoimmune and inflammatory diseases
with enhanced regulatory T-cells
Prof. David Klatzmann | Sorbonne University, France
|
|
Interleukin-2
(IL-2) is the main cytokine supporting regulatory T-cells (Tregs) development, survival and suppressive activity.
However, Tregs cannot produce IL-2 and fully
depend on exogenous IL-2.
Treg cell
therapy products are grown for weeks in culture medium containing IL-2
concentration that are 10,000-fold higher than the IL-2 serum concentration
in humans. This generates “IL-2 addicted” Tregs
that might not survive well and/or function optimally when reinjected in
patients. We reasoned that Tregs that could
produce their own IL-2 would have markedly improved therapeutic potential.
What did we discover?
|
|
|
|
|
|
|
For assistance, contact HSTalks
subscriber support:
Subscriber Support, Henry Stewart Talks Ltd
Tel: +44 (0) 20 7164 6721, Email: access@hstalks.com
Address: 40/41 Museum Street, London WC1A 1LT, United Kingdom
|
|
For more specially commissioned lectures:
|
|
